Search results for "Drug Safety"

Results 21 - 30 of about 34 for "Drug Safety".

Sort by: Relevance | Newest | Oldest

Safe prescribing can lessen overdose risk

In what one commentator called an “appalling” finding, 90% of patients in a recent study admitted to a hospital with a prescription opioid overdose eventually received another opioid prescription##mdash;often from the same clinician. Efforts to improve safe prescribing hope to fix the problem.
https://immattersacp.org/archives/2016/10/overdose.htm
1 Oct 2016

Latest diabetes drugs have a learning curve

The onus is on internists to understand the newer classes of incretins such as sodium-glucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors. They hold promise for better treatments, but they are new and not as well understood as older treatments.
https://immattersacp.org/archives/2015/10/diabetes.htm
1 Oct 2015

Changes to contraindication for statins in pregnancy

This column reviews details on recent recalls, alerts, and approvals.
https://immattersacp.org/archives/2021/09/changes-to-contraindication-for-statins-in-pregnancy.htm
1 Sep 2021

New warning for testosterone, approval for inhaled insulin

This update covers a revised warning on testosterone products about the risk of venous thromboembolism, and approval of a fast-acting inhaled insulin to treat diabetes in adults.
https://immattersacp.org/archives/2014/09/fda.htm
1 Sep 2014

New grass allergy treatment, opioid overdose solution

This update covers approval of an allergen extract to treat allergic rhinitis induced by grass pollen and of a handheld injector of naloxone for emergency treatment of known or suspected opioid overdose.
https://immattersacp.org/archives/2014/06/fda.htm
1 Jun 2014

Expanded approval on rivaroxaban, reassurance on dabigatran

This regulatory update covers an expanded indication for rivaroxaban and an announcement that bleeding rates do not appear to be higher with dabigatran than with warfarin.
https://immattersacp.org/archives/2013/01/fda.htm
1 Jan 2013

Recommended: Move hydrocodone combo products to schedule II

This regulatory update covers a proposed reclassification of hydrocodone combination products from schedule III to schedule II, and approval of an extended-release version of hydrocodone bitartrate for pain management.
https://immattersacp.org/archives/2014/01/fda.htm
1 Jan 2014